Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Smith & Nephew Temettü

Temettü kriter kontrolleri 3/6

Smith & Nephew şu anki getirisi 2.6% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi olan 8th November, 2024 temettüden önceki tarihi 4th October, 2024 dir.

Anahtar bilgiler

2.5%

Temettü verimi

107%

Ödeme oranı

Sektör ortalama getirisi	1.6%
Bir sonraki temettü ödeme tarihi	08 Nov 24
Eski temettü tarihi	04 Oct 24
Hisse başına temettü	US$0.375
Hisse başına kazanç	US$0.35
Temettü verim tahmini	3.2%

Son temettü güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SNN şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: SNN şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Smith & Nephew Piyasaya Karşı Temettü Getirisi

SNN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SNN)	2.5%
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (SNN) (3 yıla kadar)	3.2%

Önemli Temettü: SNN 'in temettüsü ( 2.43% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.42% ) daha yüksektir.

Yüksek Temettü: SNN 'in temettüsü ( 2.43% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.33% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 107.1% ) nedeniyle SNN 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Yüksek nakit ödeme oranı ( 108.6% ) nedeniyle, SNN 'un temettü ödemeleri nakit akışları tarafından yeterince karşılanmıyor.

Smith & Nephew Temettü

Temettü kriter kontrolleri 3/6

Anahtar bilgiler

Son temettü güncellemeleri

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Recent updates

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew Delivering On Its Turnaround Promise

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew: Work To Be Done But Still Long-Term Potential

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew Getting More Interesting As A Contrarian Idea

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew reports FY earnings; initiates FY23 guidance

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew: Potential Only Has Value If You Can Execute

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith & Nephew: Still A Buy Despite Short-Term Challenges

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith &amp; Nephew 1H 2022 Earnings Preview

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith+Nephew launches app Wound Compass to help reduce variation in wound care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith & Nephew: Valuation Looking More Attractive

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith & Nephew plc: Improving Performance Reflected In Price

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew plc Announces Appointment of John Ma as Non-Executive Director, Effective 17 February 2021

Smith & Nephew: Pandemic Long Tail Reduces Attractiveness

Smith & Nephew 1H 2022 Earnings Preview